PuSH - Publication Server of Helmholtz Zentrum München

Journal browsing

29 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Barbone, G.E.* et al.: X-ray multiscale 3D neuroimaging to quantify cellular aging and neurodegeneration postmortem in a model of Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging, DOI: 10.1007/s00259-022-05896-5 (2022)
2.
Ma, R. et al.: An encoder-decoder network for direct image reconstruction on sinograms of a long axial field of view PET. Eur. J. Nucl. Med. Mol. Imaging, DOI: 10.1007/s00259-022-05861-2 (2022)
3.
Spohn, S.K.B.* et al.: The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis. Eur. J. Nucl. Med. Mol. Imaging, DOI: 10.1007/s00259-022-05931-5 (2022)
4.
Fang, H.Y.* et al.: Targeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus. Eur. J. Nucl. Med. Mol. Imaging, DOI: 10.1007/s00259-021-05582-y (2021)
5.
Paprottka, K.J.* et al.: Fully automated analysis combining [18F]-FET-PET and multiparametric MRI including DSC perfusion and APTw imaging: a promising tool for objective evaluation of glioma progression. Eur. J. Nucl. Med. Mol. Imaging, DOI: 10.1007/s00259-021-05427-8 (2021)
6.
Kessel, K.A. et al.: Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome. Eur. J. Nucl. Med. Mol. Imaging 47, 1391-1399 (2020)
7.
Peeken, J.C. et al.: A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients. Eur. J. Nucl. Med. Mol. Imaging 47, 2968-2977 (2020)
8.
Schmidt-Hegemann, N.S.* et al.: Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study. Eur. J. Nucl. Med. Mol. Imaging 47, 1852-1863 (2020)
9.
Vogel, M.M. et al.: Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. Eur. J. Nucl. Med. Mol. Imaging 47, 2328-2338 (2020)
10.
Laitinen, I.* et al.: Assessment of in vivo glucagon receptor engagement in rat liver. Eur. J. Nucl. Med. Mol. Imaging 46, S707-S708 (2019)
11.
Bolch, W.E.* et al.: The ICRP reference pediatric phantoms - design, construction, and applications to nuclear medicine dosimetry. Eur. J. Nucl. Med. Mol. Imaging 45, S79-S79 (2018)
12.
Höllriegl, V. & Li, W.B.: Application of new ICRP biokinetic models for pharmacokinetic modelling of Radium-223 used for treatment of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 45, S242-S242 (2018)
13.
Karimi Ghodoosi, E. et al.: Comparison of absorbed dose to kidneys using quantitative SPECT/CT and whole body planar images for Lu-177-PSMA I&T in prostate cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 45, S112-S113 (2018)
14.
Li, W.B. et al.: Feasibility study of applying ICRP biokinetic models for pharmacokinetic modelling of alpha-emitter thorium-227 used in targeted radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 45, S125-S125 (2018)
15.
Ma, R.* ; Qiu, R.* ; Li, W.B. & Li, J.*: Patient specific internal dose estimation based on quantitative SPECT\CT imaging. Eur. J. Nucl. Med. Mol. Imaging 45, S359-S359 (2018)
16.
Schiller, K.* et al.: Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 44, 1656–1662 (2017)
17.
Handkiewicz-Junak, D.* et al.: Gene signature of the post-Chernobyl papillary thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 43, 1267-1277 (2016)
18.
Kijanka, M.* et al.: Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur. J. Nucl. Med. Mol. Imaging 40, 1718-1729 (2013)
19.
Essler, M.* et al.: Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur. J. Nucl. Med. Mol. Imaging 39, 602-612 (2012)
20.
Graf, N.* et al.: [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. Eur. J. Nucl. Med. Mol. Imaging 40, 34-43 (2012)